These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24150908)

  • 1. Tracking motor impairments in the progression of Huntington's disease.
    Long JD; Paulsen JS; Marder K; Zhang Y; Kim JI; Mills JA;
    Mov Disord; 2014 Mar; 29(3):311-9. PubMed ID: 24150908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivariate prediction of motor diagnosis in Huntington's disease: 12 years of PREDICT-HD.
    Long JD; Paulsen JS;
    Mov Disord; 2015 Oct; 30(12):1664-72. PubMed ID: 26340420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.
    Paulsen JS; Long JD; Ross CA; Harrington DL; Erwin CJ; Williams JK; Westervelt HJ; Johnson HJ; Aylward EH; Zhang Y; Bockholt HJ; Barker RA;
    Lancet Neurol; 2014 Dec; 13(12):1193-201. PubMed ID: 25453459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor onset and diagnosis in Huntington disease using the diagnostic confidence level.
    Liu D; Long JD; Zhang Y; Raymond LA; Marder K; Rosser A; McCusker EA; Mills JA; Paulsen JS;
    J Neurol; 2015 Dec; 262(12):2691-8. PubMed ID: 26410751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive decline in prodromal Huntington Disease: implications for clinical trials.
    Paulsen JS; Smith MM; Long JD;
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1233-9. PubMed ID: 23911948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic criteria for Huntington's disease based on natural history.
    Reilmann R; Leavitt BR; Ross CA
    Mov Disord; 2014 Sep; 29(11):1335-41. PubMed ID: 25164527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a prognostic index for Huntington's disease.
    Long JD; Langbehn DR; Tabrizi SJ; Landwehrmeyer BG; Paulsen JS; Warner J; Sampaio C
    Mov Disord; 2017 Feb; 32(2):256-263. PubMed ID: 27892614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis.
    Long JD; Mills JA; Leavitt BR; Durr A; Roos RA; Stout JC; Reilmann R; Landwehrmeyer B; Gregory S; Scahill RI; Langbehn DR; Tabrizi SJ;
    JAMA Neurol; 2017 Nov; 74(11):1352-1360. PubMed ID: 28975278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial.
    Langbehn DR; Fine EM; Meier A; Hersch S
    Mov Disord; 2022 May; 37(5):1040-1046. PubMed ID: 35170086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data.
    Epping EA; Kim JI; Craufurd D; Brashers-Krug TM; Anderson KE; McCusker E; Luther J; Long JD; Paulsen JS;
    Am J Psychiatry; 2016 Feb; 173(2):184-92. PubMed ID: 26472629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.
    Fusilli C; Migliore S; Mazza T; Consoli F; De Luca A; Barbagallo G; Ciammola A; Gatto EM; Cesarini M; Etcheverry JL; Parisi V; Al-Oraimi M; Al-Harrasi S; Al-Salmi Q; Marano M; Vonsattel JG; Sabatini U; Landwehrmeyer GB; Squitieri F
    Lancet Neurol; 2018 Nov; 17(11):986-993. PubMed ID: 30243861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.
    Biglan KM; Ross CA; Langbehn DR; Aylward EH; Stout JC; Queller S; Carlozzi NE; Duff K; Beglinger LJ; Paulsen JS;
    Mov Disord; 2009 Sep; 24(12):1763-72. PubMed ID: 19562761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
    ; Biglan KM; Shoulson I; Kieburtz K; Oakes D; Kayson E; Shinaman MA; Zhao H; Romer M; Young A; Hersch S; Penney J; Marder K; Paulsen J; Quaid K; Siemers E; Tanner C; Mallonee W; Suter G; Dubinsky R; Gray C; Nance M; Bundlie S; Radtke D; Kostyk S; Baic C; Caress J; Walker F; Hunt V; O'Neill C; Chouinard S; Factor S; Greenamyre T; Wood-Siverio C; Corey-Bloom J; Song D; Peavy G; Moskowitz C; Wesson M; Samii A; Bird T; Lipe H; Blindauer K; Marshall F; Zimmerman C; Goldstein J; Rosas D; Novak P; Caviness J; Adler C; Duffy A; Wheelock V; Tempkin T; Richman D; Seeberger L; Albin R; Chou KL; Racette B; Perlmutter JS; Perlman S; Bordelon Y; Martin W; Wieler M; Leavitt B; Raymond L; Decolongon J; Clarke L; Jankovic J; Hunter C; Hauser RA; Sanchez-Ramos J; Furtado S; Suchowersky O; Klimek ML; Guttman M; Sethna R; Feigin A; Cox M; Shannon B; Percy A; Dure L; Harrison M; Johnson W; Higgins D; Molho E; Nickerson C; Evans S; Hobson D; Singer C; Galvez-Jimenez N; Shannon K; Comella C; Ross C; Saint-Hilaire MH; Testa C; Rosenblatt A; Hogarth P; Weiner W; Como P; Kumar R; Cotto C; Stout J; Brocht A; Watts A; Eberly S; Weaver C; Foroud T; Gusella J; MacDonald M; Myers R; Fahn S; Shults C
    JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal assessment of the Unified Huntington's Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington's disease.
    Winder JY; Achterberg WP; Gardiner SL; Roos RAC
    Eur J Neurol; 2019 May; 26(5):780-785. PubMed ID: 30576046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline multimodal information predicts future motor impairment in premanifest Huntington's disease.
    Castro E; Polosecki P; Rish I; Pustina D; Warner JH; Wood A; Sampaio C; Cecchi GA
    Neuroimage Clin; 2018; 19():443-453. PubMed ID: 29984153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Joint modeling of multivariate longitudinal data and survival data in several observational studies of Huntington's disease.
    Long JD; Mills JA
    BMC Med Res Methodol; 2018 Nov; 18(1):138. PubMed ID: 30445915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Huntington's disease decades before diagnosis: the Predict-HD study.
    Paulsen JS; Langbehn DR; Stout JC; Aylward E; Ross CA; Nance M; Guttman M; Johnson S; MacDonald M; Beglinger LJ; Duff K; Kayson E; Biglan K; Shoulson I; Oakes D; Hayden M;
    J Neurol Neurosurg Psychiatry; 2008 Aug; 79(8):874-80. PubMed ID: 18096682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating motor progression of juvenile-onset Huntington's Disease: An Enroll-HD analysis.
    Nopoulos S; Reasoner EE; Ogilvie AC; Killoran A; Schultz JL
    Parkinsonism Relat Disord; 2024 Feb; 119():105954. PubMed ID: 38142629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huntington's Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales.
    Sun W; Zhou D; Warner JH; Langbehn DR; Hochhaus G; Wang Y
    J Clin Pharmacol; 2020 Aug; 60(8):1051-1060. PubMed ID: 32416008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.